Monitor the upcoming webcast for clinical data strength, but assess whether the results justify the legal risk. Watch for any escalation in the RevMed dispute, including a formal lawsuit filing or preliminary injunction motion, which could severely impact ERAS-0015's development timeline and valuation.
Price Chart
Executive Summary
Erasca disclosed preliminary Phase 1 data for its RAS-targeting drug ERAS-0015 while simultaneously revealing a patent and trade secret infringement claim from Revolution Medicines. The litigation threat over a key asset creates significant near-term uncertainty despite the positive clinical update.
Key Facts
- Erasca announced a webcast to discuss preliminary Phase 1 dose escalation data for ERAS-0015, a pan-RAS molecular glue for RAS-mutant solid tumors.
- Revolution Medicines (RevMed) alleged that ERAS-0015 infringes its U.S. Patent No. 12,409,225 under the doctrine of equivalents.
- RevMed also claimed Erasca is liable for misappropriation of trade secrets related to ERAS-0015 and accused the company of making deceptive comparative statements.
- RevMed demanded Erasca cease all development and commercialization activities for ERAS-0015 in the U.S. outside the Hatch-Waxman safe harbor.
- Erasca stated it believes the allegations are without merit and intends to contest them vigorously.
Financial Impact
High risk to future revenue potential of ERAS-0015; potential for significant legal costs, injunction, or royalty payments if litigation escalates.
Risk Factors
- ERAS-0015 development could be halted or delayed by litigation.
- Potential for material financial liability through damages or royalties if infringement is found.
- Reputational damage from trade secret allegations and comparative claims.
- Clinical data may be overshadowed by legal overhang, limiting positive market reaction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179214 |
| Document: 0001193125-26-179214-index-headers.html | 0001193125-26-179214 |
| Document: 0001193125-26-179214-index.html | 0001193125-26-179214 |
| Document: 0001193125-26-179214.txt | 0001193125-26-179214 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | 8-K | $17.60 $15.55 | ▼ −11.65% | ▼ −12.96% | $14.94 (−15.09%) |
Aug 17, 2026 6w ago | 144 | $18.28 $16.16 | ▼ −11.60% | ▼ −10.07% | $14.94 (−18.24%) |
Aug 13, 2026 7w ago | Institutional Cluster | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 12, 2026 7w ago | 3 | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 11, 2026 7w ago | Press Release | $18.58 $16.03 | ▼ −13.72% | ▼ −11.83% | $14.94 (−19.56%) |
Jul 22, 2026 10w ago | Press Release | $19.51 $18.07 | ▲ +7.38% | ▲ +10.28% | $14.94 (+23.40%) |
Jul 14, 2026 11w ago | 8-K | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | 424B5 | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | Press Release | $19.50 $18.31 | ▲ +6.10% | ▲ +8.59% | $14.94 (+23.36%) |
Jul 13, 2026 11w ago | Press Release | $19.50 $18.31 | ▼ −6.10% | ▼ −8.59% | $14.94 (−23.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access